The standard of care for hematologic malignancies (including acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphoblastic leukemia, chronic myeloid leukemia, multiple myeloma, and myelodysplastic syndrome) includes radiation and chemotherapy followed by bone marrow transplantation. This project aims to instead treat hematologic malignancies by using in-vivo or extracorporeal sonodynamic therapy (SDT) following the administration of the company’s proprietary compound. SDT is currently showing promise in clinical trials for treatment of solid tumors. The STHM project aims to expand the use of SDT in hematologic malignancies through multiple novel approaches, including in circulating blood or via catheterization into a custom milli-fluidics device. If successful, the resulting treatment would be minimally- or non-invasive and would increase treatment efficacy, increase patient comfort, and decrease costs.